KR20220139414A - 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물 - Google Patents

글리타존 및 nrf2 활성화제를 포함하는 약학 조성물 Download PDF

Info

Publication number
KR20220139414A
KR20220139414A KR1020227033805A KR20227033805A KR20220139414A KR 20220139414 A KR20220139414 A KR 20220139414A KR 1020227033805 A KR1020227033805 A KR 1020227033805A KR 20227033805 A KR20227033805 A KR 20227033805A KR 20220139414 A KR20220139414 A KR 20220139414A
Authority
KR
South Korea
Prior art keywords
ppar gamma
pioglitazone
gamma agonist
nrf2
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227033805A
Other languages
English (en)
Korean (ko)
Inventor
뵈른 콜린 카르스
Original Assignee
뵈른 콜린 카르스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48610741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220139414(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 뵈른 콜린 카르스 filed Critical 뵈른 콜린 카르스
Priority claimed from KR1020207033841A external-priority patent/KR20200140384A/ko
Publication of KR20220139414A publication Critical patent/KR20220139414A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227033805A 2011-12-19 2012-12-10 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물 Ceased KR20220139414A (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP11194292 2011-12-19
EP11194292.6 2011-12-19
EP12004652 2012-06-21
EP12004652.9 2012-06-21
US201261663761P 2012-06-25 2012-06-25
US61/663,761 2012-06-25
US13/654,632 2012-10-18
US13/654,632 US20130158077A1 (en) 2011-12-19 2012-10-18 Pharmaceutical compositions
KR1020207033841A KR20200140384A (ko) 2011-12-19 2012-12-10 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물
PCT/EP2012/074915 WO2013092269A1 (en) 2011-12-19 2012-12-10 Pharmaceutical compositions comprising glitazones and nrf2 activators

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207033841A Division KR20200140384A (ko) 2011-12-19 2012-12-10 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
KR20220139414A true KR20220139414A (ko) 2022-10-14

Family

ID=48610741

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147019944A Active KR102188487B1 (ko) 2011-12-19 2012-12-10 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물
KR1020227033805A Ceased KR20220139414A (ko) 2011-12-19 2012-12-10 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020147019944A Active KR102188487B1 (ko) 2011-12-19 2012-12-10 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물

Country Status (18)

Country Link
US (6) US20130158077A1 (OSRAM)
EP (1) EP2793876B1 (OSRAM)
JP (1) JP6132850B2 (OSRAM)
KR (2) KR102188487B1 (OSRAM)
CN (1) CN103998035B (OSRAM)
AR (1) AR089301A1 (OSRAM)
AU (4) AU2012358420B9 (OSRAM)
BR (1) BR112014014809A2 (OSRAM)
CA (1) CA2859635C (OSRAM)
CL (1) CL2014001639A1 (OSRAM)
EA (1) EA201400729A1 (OSRAM)
ES (1) ES2959111T3 (OSRAM)
HK (1) HK1200711A1 (OSRAM)
IL (1) IL233134A0 (OSRAM)
MX (2) MX2014007254A (OSRAM)
PH (1) PH12014501029A1 (OSRAM)
SG (1) SG11201403241XA (OSRAM)
WO (1) WO2013092269A1 (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
SG182629A1 (en) 2010-02-18 2012-08-30 High Point Pharmaceuticals Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
EP2887935A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014093114A1 (en) * 2012-12-11 2014-06-19 Metabolic Solutions Development Company Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
PT2970101T (pt) 2013-03-14 2018-10-04 Alkermes Pharma Ireland Ltd Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
WO2016074684A1 (en) * 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
KR101704410B1 (ko) 2015-07-22 2017-02-22 대구가톨릭대학교산학협력단 사파논 a를 함유하는 심혈관질환의 예방 및 치료용 조성물
MX2018005345A (es) * 2015-10-28 2018-08-14 Sun Pharmaceutical Ind Ltd Composiciones farmaceuticas de dimetil fumarato.
CN114617868A (zh) * 2016-02-03 2022-06-14 参宿七制药股份有限公司 Nrf2活化性化合物及其用途
CN106389457A (zh) * 2016-11-30 2017-02-15 胡立志 PPAR‑γ激动剂在制备治疗脱发药物中的应用及治疗脱发的药物
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
CN108685903B (zh) * 2018-07-05 2019-10-18 陕西师范大学 鼠尾草酚在制备防治实验性自身免疫性脑脊髓炎药物的应用
WO2020094767A1 (en) 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of nrf2 activators for the treatment of staphylococcus aureus infections
KR20210096162A (ko) * 2018-11-27 2021-08-04 쿄와 기린 가부시키가이샤 의약 조성물
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
CN111606828B (zh) * 2019-02-22 2023-07-28 浙江海正药业股份有限公司 (E)-α,β-不饱和酰胺化合物的晶型及其制备方法和用途
CN109846867A (zh) * 2019-03-29 2019-06-07 北京中医药大学 花姜酮用于制备抗心肌缺血的药物的用途
DE112020002996T5 (de) * 2019-08-05 2022-05-19 Agency For Science, Technology And Research Polylysin-Polymere mit antimikrobieller und/oder krebsbekämpfender Aktivität
CN110279866B (zh) * 2019-08-12 2021-06-29 浙江养生堂天然药物研究所有限公司 包含柠檬苦素类化合物和噻唑烷二酮类药物的组合产品
CN110613712B (zh) * 2019-10-22 2021-06-29 上海交通大学医学院附属第九人民医院 中药组合物及其在治疗血管炎症和内皮损伤中的应用
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CN113244221B (zh) * 2020-02-12 2022-10-25 华东师范大学 双甲基鼠尾草酚在制备治疗恶病质疾病的药物中的应用
WO2021173658A1 (en) * 2020-02-24 2021-09-02 Hofmann Robert F Naphthoquinone-based chalcone derivatives and uses thereof
US20230134760A1 (en) * 2020-03-04 2023-05-04 Hongbing Wang Car and nrf2 dual activator agents for cyclophosphamide-based and doxorubicin-based treatments of cancer
US20230099229A1 (en) * 2020-03-13 2023-03-30 Reprise Pharmaceuticals, Inc. Methods of treating multiple sclerosis
CN111574437A (zh) * 2020-06-22 2020-08-25 上海长车生物科技有限公司 (e)-3-芳杂环基丙-2-烯酸衍生物及其制备和用途
CN111529514A (zh) * 2020-06-23 2020-08-14 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种特丁基对苯二酚的应用及治疗椎间盘退变的药物
JP2023541192A (ja) * 2020-09-14 2023-09-28 トリテルペノイド・セラピューティクス・インコーポレイテッド ＣＤＤＯ－２Ｐ－Ｉｍ及びＣＤＤＯ－３Ｐ－Ｉｍの類似体
WO2023158678A1 (en) * 2022-02-15 2023-08-24 Emory University Fumaric acid esters, inhalation administration methods, pharmaceutical uses and compositions
KR20230123323A (ko) 2022-02-16 2023-08-23 대구대학교 산학협력단 알릴 이소티오시아네이트(Allyl isothiocyanate)를 유효성분으로 포함하는 골 대사성 질환의 예방, 개선 또는 치료용 조성물
CN114414809B (zh) * 2022-03-28 2022-06-21 中元伯瑞生物科技(珠海横琴)有限公司 用于诊断尘肺病的生物标志物的应用
EP4580612A1 (en) 2022-09-02 2025-07-09 Institut National de la Santé et de la Recherche Médicale Use of nrf2 activators for the treatment of cerebral small vessel disease
CN117137897B (zh) * 2023-10-31 2024-02-13 中国中医科学院中药研究所 索法酮在制备用于预防/治疗银屑病的药物中的应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US807113A (en) 1905-03-27 1905-12-12 Frederick O Dyer Puzzle.
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DE10199003I1 (de) 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
SG148834A1 (en) 1999-06-30 2009-01-29 Japan Tobacco Inc Compounds for the modulation of ppary activity
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US6403121B1 (en) 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
US20040013643A1 (en) 2000-09-19 2004-01-22 Novlmmune S.A. Methods for treatment of multiple sclerosis with statins
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
SK288238B6 (sk) 2001-01-12 2015-01-07 Fumapharm Ag Amidy kyseliny fumarovej
GB2373725A (en) 2001-03-30 2002-10-02 Novartis Ag Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production
CA2440017A1 (en) * 2001-05-03 2002-11-14 Cornell Research Foundation, Inc. Treatment of hpv caused diseases
FR2825023B1 (fr) 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
BRPI0407074A (pt) 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
WO2004098510A2 (en) * 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy
EP1913942B1 (en) 2003-09-09 2009-11-11 Biogen Idec International GmbH The use of fumaric acid derivatives for inhibition of PGF-induced thymidine uptake of bronchial smooth muscle cells and for inhibition of bronchial smooth cells proliferation
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
WO2005055933A2 (en) 2003-12-03 2005-06-23 Smithkline Beecham Corporation Treatment of psoriasis with rosiglitazone
EP1722789A2 (en) 2004-03-08 2006-11-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
BRPI0512856A (pt) 2004-06-30 2008-04-08 Combinatorx Inc métodos e reagentes para o tratamento de distúrbios metabólicos
ITMI20041825A1 (it) 2004-09-24 2004-12-24 Medestea Res & Production Srl Agonisti dei ricettori attivanti la proliferazione dei perossisomi, utili nella prevenzione o nel trattamento della gastrite
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US20080004344A1 (en) 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
GB0504206D0 (en) 2005-03-01 2005-04-06 Glaxo Group Ltd Combination therapy
DE102005022845A1 (de) 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
EP1915387B1 (en) 2005-07-07 2010-01-20 Aditech Pharma AG Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
EP1940382A2 (en) 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007042034A1 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
JP5179363B2 (ja) 2005-12-22 2013-04-10 武田薬品工業株式会社 固形製剤
JP5230610B2 (ja) 2006-05-05 2013-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
AU2007299920A1 (en) 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
EP3135282A1 (en) 2007-02-08 2017-03-01 Biogen MA Inc. Neuroprotection in demyelinating diseases
EP2680009A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
CA2693628A1 (en) 2007-07-11 2009-01-15 Cardoz Ab New combination for use in the treatment of imflammatory disorders
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
ME03529B (me) 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
WO2009097997A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
DE102008030023A1 (de) 2008-06-16 2009-12-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit
GB0913672D0 (en) 2009-08-05 2009-09-16 Argenta Discovery Ltd Glitazones
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
US20110190242A1 (en) * 2008-09-23 2011-08-04 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2010040055A2 (en) 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
JP5775464B2 (ja) 2009-02-13 2015-09-09 リアタ ファーマシューティカルズ，インク 非晶質ｃｄｄｏ−ｍｅを含有する遅延放出性経口投薬組成物
EP3318249A1 (en) 2009-04-29 2018-05-09 Biogen MA Inc. Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis
WO2011039175A1 (en) * 2009-09-29 2011-04-07 Bodo Melnik Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
NZ600421A (en) 2009-12-15 2014-06-27 Metabolic Solutions Dev Co Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
ME02317B (me) 2010-02-12 2016-06-20 Biogen Ma Inc Neuroprotekcija kod demijelinizacijskih bolesti
US8486922B2 (en) * 2010-04-28 2013-07-16 Chien-Hung Chen Composition
CA2811634C (en) 2010-09-21 2019-01-15 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
WO2012068454A2 (en) 2010-11-19 2012-05-24 University Of Rochester Nrf2 deficiency influences susceptibility to steroid resistance via hdac2 reduction
CN102552140B (zh) * 2011-01-12 2013-05-29 北京人福军威医药技术开发有限公司 罗格列酮的液体组合物
CA2865316A1 (en) 2011-04-28 2012-11-01 Gino Cortopassi Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
WO2013022882A1 (en) 2011-08-08 2013-02-14 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy for treatment of inflammatory demyelinating disease
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
LT2841445T (lt) 2012-04-27 2017-09-11 Reata Pharmaceuticals, Inc. Bardoksolonmetilo 2,2-difluorpropionamido dariniai, polimorfinės formos ir jų panaudojimo būdai
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
EP2950798B1 (en) 2013-01-30 2021-05-12 Intekrin Therapeutics, Inc. Ppar-gamma agonist for treatment of multiple sclerosis
MA38385A1 (fr) 2013-04-22 2017-09-29 Cadila Healthcare Ltd Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
SG11201608218QA (en) 2014-04-02 2016-10-28 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2016074684A1 (en) 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
BR112019004791A2 (pt) 2016-09-13 2019-06-04 Intekrin Therapeutics Inc tratamento de esclerose múltipla com chs-131
US11382889B2 (en) 2018-04-19 2022-07-12 Institut D'investigació Biomèdica De Bellvitge (Idibell) NRF2 activators for the prevention and/or treatment of axonal degeneration
KR20210031435A (ko) 2018-06-06 2021-03-19 미노릭스 테라퓨틱스 에스.엘. 치료학적 유효량의 5-[[4-[2-[5-(1-히드록시에틸)피리딘-2-일]에톡시]페닐]메틸]-1,3-티아졸리딘-2,4-디온을 투여하는 방법
BR112020024939A2 (pt) 2018-06-06 2021-03-09 Minoryx Therapeutics S.L. Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]benzil]-1,3-tiazolidina-2,4-diona e seus sais
SI3801515T1 (sl) 2018-06-06 2025-07-31 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni

Also Published As

Publication number Publication date
KR102188487B1 (ko) 2020-12-09
EA201400729A1 (ru) 2014-12-30
JP6132850B2 (ja) 2017-05-24
KR20140113689A (ko) 2014-09-24
CN103998035A (zh) 2014-08-20
US12083107B2 (en) 2024-09-10
CN103998035B (zh) 2017-10-24
MX394473B (es) 2025-03-24
US11484530B2 (en) 2022-11-01
AU2012358420B2 (en) 2017-06-15
JP2015504871A (ja) 2015-02-16
MX2014007254A (es) 2014-08-01
PH12014501029A1 (en) 2014-06-23
AU2017225019B2 (en) 2019-04-11
AU2021201390B2 (en) 2023-02-09
BR112014014809A8 (pt) 2017-06-13
US10426763B2 (en) 2019-10-01
AU2021201390A1 (en) 2021-03-18
CA2859635A1 (en) 2013-06-27
CA2859635C (en) 2022-06-21
ES2959111T3 (es) 2024-02-20
AU2012358420A1 (en) 2014-07-31
US20230190720A1 (en) 2023-06-22
US20240423967A1 (en) 2024-12-26
HK1200711A1 (en) 2015-08-14
IL233134A0 (en) 2014-07-31
AU2012358420B9 (en) 2017-06-29
WO2013092269A1 (en) 2013-06-27
BR112014014809A2 (pt) 2017-06-13
EP2793876A1 (en) 2014-10-29
AU2017225019A1 (en) 2017-09-28
US20190381023A1 (en) 2019-12-19
AU2019204493B2 (en) 2020-12-03
EP2793876C0 (en) 2023-10-04
US20130158077A1 (en) 2013-06-20
AR089301A1 (es) 2014-08-13
SG11201403241XA (en) 2014-07-30
US20130172391A1 (en) 2013-07-04
EP2793876B1 (en) 2023-10-04
CL2014001639A1 (es) 2014-11-14
US20170065571A1 (en) 2017-03-09
AU2019204493A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
US12083107B2 (en) Pharmaceutical compositions comprising glitazones and Nrf2 activators
TWI407955B (zh) 高脂血症之預防及／或治療劑
JP2015044855A (ja) 神経変性および神経炎症の治療
US11497748B2 (en) Method for activating AMPK and the use of adenine
WO2017044551A1 (en) Ppar-alpha agonists for treating mitochondrial diseases
US9504679B2 (en) Pharmaceutical compositions comprising glitazones and Nrf2 activators
KR20100135700A (ko) 지방성 간 질환의 치료용 의약 조성물
US20230098944A1 (en) Method of decreasing amyloid beta monomer levels in patients with cognitive decline
TW201334776A (zh) 醫藥組成物
KR20200140384A (ko) 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물
EA046719B1 (ru) Способ лечения аутоиммунного и/или воспалительного нарушения, выбранного из рассеянного склероза или клинически изолированного синдрома (cis), фармацевтическая композиция, твердая пероральная лекарственная форма и набор для применения в указанном способе
HK1138277B (en) Prophylactic and/or therapeutic agent for hyperlipemia

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220928

Application number text: 1020207033841

Filing date: 20201124

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230120

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230724

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230120

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I